
Lexington Biosciences Holdings Corp. Stock Analysis LXGTF
Lexington Biosciences, Inc. is a medical device company, which engages in the research and development of non-diagnostic devices. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-06-01. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The firm is in the final stages of releasing the developed product for clinical studies. The firm's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
Read More Lexington Biosciences Holdings Corp (LXGTF) Chart
Key Statistics of Lexington Biosciences Holdings Corp (LXGTF)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
200.00P/E Ratio (TTM)
-52 Week Range
Market Cap
-Avg. Volume
200.00Dividend Yield
-Financial Metrics & Statements of Lexington Biosciences Holdings Corp (LXGTF)
FAQ's for Lexington Biosciences Holdings Corp (LXGTF)
- According to Musaffa’s Shariah screening methodology, Lexington Biosciences Holdings Corp (LXGTF) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.